MANDELBOIM; Ofer

Patent Applications and Registrations

Patent applications and USPTO patent grants for MANDELBOIM; Ofer.The latest application filed is for "antibodies specific to human nectin-2".

Company Profile

7.8.17

MANDELBOIM; Ofer - Shoham IL
MANDELBOIM; Ofer - Shoam IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antibodies Specific To Human Nectin-2 App 20220112283 - MANDELBOIM; Ofer ; et al.	2022-04-14
Antibodies Specific To Human T-cell Immunoglobulin And Itim Domain (tigit) App 20210220472 - MANDELBOIM; Ofer ; et al.	2021-07-22
Antibodies Specific To Human Nectin4 App 20210130459 - MANDELBOIM; Ofer ; et al.	2021-05-06
Antibodies Specific To Human Poliovirus Receptor (pvr) App 20210115150 - MANDELBOIM; Ofer ; et al.	2021-04-22
Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) Grant 10,946,095 - Mandelboim , et al. March 16, 2	2021-03-16
Attenuated or inactivated pathogenic Escherichia coli for treating urogenital cancer Grant 10,918,677 - Mandelboim , et al. February 16, 2	2021-02-16
Antibodies specific to human poliovirus receptor (PVR) Grant 10,906,987 - Mandelboim , et al. February 2, 2	2021-02-02
Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same Grant 10,716,864 - Mandelboim , et al.	2020-07-21
Antibodies Specific To Human Poliovirus Receptor (pvr) App 20200040092 - MANDELBOIM; Ofer ; et al.	2020-02-06
Attenuated Or Inactivated Pathogenic Escherichia Coli For Treating Urogenital Cancer App 20180333439 - MANDELBOIM; Ofer ; et al.	2018-11-22
Anti-nkp46 Antibodies, Toxin Conjugates, And Therapeutic Use Of Same App 20180207290 - MANDELBOIM; Ofer ; et al.	2018-07-26
Antibodies Specific To Human T-cell Immunoglobulin And Itim Domain (tigit) App 20180185480 - MANDELBOIM; Ofer ; et al.	2018-07-05
Methods And Compositions For Treating Cancer App 20180028601 - BACHRACH; Gilad Benjamin ; et al.	2018-02-01
Method of treating type 1 diabetes by administering NKp46 polypeptide Grant 8,980,244 - Mandelboim , et al. March 17, 2	2015-03-17
Method For Treating Type 1 Diabetes App 20130280209 - MANDELBOIM; Ofer ; et al.	2013-10-24
Method of treating diabetes by administering an anti-NKp46 antibody Grant 8,420,092 - Mandelboim , et al. April 16, 2	2013-04-16
Use Of Nkp46 For Preventing Diabetes App 20120076753 - Mandelboim; Ofer ; et al.	2012-03-29
Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells Grant 7,825,085 - Mandelboim , et al. November 2, 2	2010-11-02
NK Cell Receptor Conjugates for Treating Malignancies App 20100047169 - MANDELBOIM; Ofer ; et al.	2010-02-25
Peptides Derived from Natural Cytotoxicity Receptors and Methods of Use Thereof App 20070280938 - Mandelboim; Ofer ; et al.	2007-12-06
Fragments of nkp44 for targeting viral-infected and tumor cells App 20070203054 - Mandelboim; Ofer	2007-08-30
Nk cell receptor conjugates for treating malignancies App 20060165592 - Mandelboim; Ofer ; et al.	2006-07-27
Nk cells activiating receptors and their therapeutic and diagnostic uses App 20040072256 - Mandelboim, Ofer ; et al.	2004-04-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.